Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis
Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis
批准号:
7336264
负责人:
MARK A JACOBSON
金额:
$23.11万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-09-01 至 2009-08-31
关键词:
AccountingAcquired Immunodeficiency SyndromeAnimal ModelAnti-Retroviral AgentsAntibodiesAntigensAsiaAutoimmune ProcessBackBiological AssayBlindnessCD4 Positive T LymphocytesCD8B1 geneCell physiologyCellsClinicalColorComplicationCountryCytomegalovirusCytomegalovirus RetinitisCytotoxic T-LymphocytesDataDevelopmentDiagnosisDiagnosticDiseaseEnrollmentEquilibriumEuropeEyeFlow CytometryFrequenciesHomeostasisIL2RA geneImmuneIncidenceInflammationInterferon Type IIInterferonsInterleukin 2 ReceptorInterleukin-2LightLongitudinal StudiesMeasurementMeasuresMediatingMonoclonal Antibody HuM291Muromonab-CD3Natural HistoryNecrosisNumbersObservational StudyParentsPathogenesisPatientsPatternPeripheral Blood Mononuclear CellPharmaceutical PreparationsPublicationsRecoveryRegulationRelative (related person)ReportingResourcesRetinalRetinal DetachmentRetinitisRiskRoleScreening procedureSorting - Cell MovementSpecimenT-LymphocyteT-Lymphocyte SubsetsTestingTimeTreatment ProtocolsUveitisVisitVisual impairmentantiretroviral therapycase controlcytokinecytotoxicdesignfollow-upindexingmacular edemapreventresearch studyresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Among patients with AIDS and cytomegalovirus retinitis (CMVR) who have become immunorestored by antiretroviral therapy and can discontinue anti-CMV therapy without further retinitis progression, a new cause of visual impairment has emerged-- immune recovery uveitis (IRU). The aim of this proposal is to investigate the role that aberrant T cell function may have in the immunopathogenesis of CMV IRU. We propose to test the following hypotheses, which are suggested by our preliminary data and by recent reports with animal models of autoimmune and post-infectious uveitis: 1) that an imbalance between CMV-specific CD4+ and CD8+ T cell cytokine responses and/or a deficit in regulatory CD4+ T cells (Treg) are more common in PBMC of patients with CMV IRU than in immunorestored CMVR patients who do not develop IRU and 2) that measuring such aberrant T cell responses by flow cytometry may have potential clinical utility as a screening test to identify immunorestored CMVR patients at risk for developing IRU. This proposal has a case-control design. Stored PBMC that have already been collected in an NEI-sponsored, multicenter, observational study of CMVR natural history will be thawed and assayed by flow cytometry for CMV-specific CD4+ T cell IL-2 and CD8+ T cell IFN?, TNFa and CD107a/b responses and Treg content. Assay results will be compared from case and matched controls who were all diagnosed with AIDS and CMVR and were immunorestored by antiretroviral therapy and who did (cases) or did not (controls) have IRU diagnosed during the parent longitudinal study. The effect of depleting Treg from PBMC and of adding back flow-sorted Treg cells to Treg-depleted PBMC specimens on CMV-specific, as well as anti-CD3-induced, CD8+ T cell functional responses will also be examined in order to understand the mechanism by which Treg function may impact on CMV-specific CD8+ T cell effector responses in cases and controls. In these latter experiments, anti-IL-10 and/or anti-TGF¿ antibodies will also be used to test whether regulation of CMV-specific CD8+ T cell responses depends on these cytokines. Cytomegalovirus retinitis (CMVR) remains an important complication of AIDS in the US and Europe and is emerging as an important AIDS complication internationally, especially in Asia. In the US, CMV immune recovery uveitis (IRU) now accounts for 50% of incident vision loss in AIDS patients with longstanding CMVR and antiretroviral treatment-mediated immune recovery. There is no effective therapy for CMV IRU. Thus, understanding the disease mechanism of CMV IRU could facilitate development of effective therapy for CMV IRU or diagnostic or treatment strategies to prevent CMV IRU.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HIV Epitope Specific T Cell Responses and Control of HIV Replication
-
批准号:7282098
-
项目类别:
-
资助金额:$23.09万
-
财政年份:2007
-
负责人:MARK A JACOBSON
-
依托单位:
HIV Epitope Specific T Cell Responses and Control of HIV Replication
-
批准号:7417845
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2007
-
负责人:MARK A JACOBSON
-
依托单位:
Aberrant T Cell Function and Immunopathogenesis of CMV Immune Recovery Uveitis
-
批准号:7489883
-
项目类别:
-
资助金额:$18.93万
-
财政年份:2007
-
负责人:MARK A JACOBSON
-
依托单位:
CMV Immune Response & Long-Term Outcome of CMV Retinitis
-
批准号:6745723
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
CMV Immune Response & Long-Term Outcome of CMV Retinitis
-
批准号:6848025
-
项目类别:
-
资助金额:$25.92万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
THE ROLE OF PROTEIN LOOP FLEXIBILITY IN SUBSTRATE BINDING
-
批准号:7181783
-
项目类别:
-
资助金额:$0.1万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
AACTG 5079: PHYSIOLOGIC TESTOSTERONE
-
批准号:7203030
-
项目类别:
-
资助金额:$0.15万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
ADJUVANT RHIL-12 WITH A CYTOMEGALOVIRUS
-
批准号:7203039
-
项目类别:
-
资助金额:$30.09万
-
财政年份:2004
-
负责人:MARK A JACOBSON
-
依托单位:
AACTG 5079: Physiologic testosterone
-
批准号:7044942
-
项目类别:
-
资助金额:$0.57万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
A5159: HIV protease inhibitors and calcium channel blockers
-
批准号:7044955
-
项目类别:
-
资助金额:$0.57万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
ADJUVANT RHIL-12 WITH A CYTOMEGALOVIRUS
-
批准号:7044951
-
项目类别:
-
资助金额:$4.95万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
ACTG 5077: HAART/HIV compartments
-
批准号:7044920
-
项目类别:
-
资助金额:$0.98万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
AACTG A5082: Metformin/ Rosiglitazone
-
批准号:7044930
-
项目类别:
-
资助金额:$0.9万
-
财政年份:2003
-
负责人:MARK A JACOBSON
-
依托单位:
Adjunct rhIL-12 enhance THI response to viral vaccine?
-
批准号:6467926
-
项目类别:
-
资助金额:$50.48万
-
财政年份:2002
-
负责人:MARK A JACOBSON
-
依托单位:
Adjunct rhIL-12 enhance THI response to viral vaccine?
-
批准号:6623575
-
项目类别:
-
资助金额:$29.1万
-
财政年份:2002
-
负责人:MARK A JACOBSON
-
依托单位:
Adjunct rhIL-12 enhance THI response to viral vaccine?
-
批准号:6737543
-
项目类别:
-
资助金额:$10.37万
-
财政年份:2002
-
负责人:MARK A JACOBSON
-
依托单位:
CORE--CLINICAL
-
批准号:6453039
-
项目类别:
-
资助金额:$13.19万
-
财政年份:2001
-
负责人:MARK A JACOBSON
-
依托单位:
CORE--CLINICAL
-
批准号:6507450
-
项目类别:
-
资助金额:$16.54万
-
财政年份:2001
-
负责人:MARK A JACOBSON
-
依托单位:
CORE--CLINICAL
-
批准号:6302657
-
项目类别:
-
资助金额:$34.93万
-
财政年份:2000
-
负责人:MARK A JACOBSON
-
依托单位:
CORE--ADVANCED TECHNOLOGY LABORATORIES
-
批准号:6099319
-
项目类别:
-
资助金额:$15.75万
-
财政年份:1999
-
负责人:MARK A JACOBSON
-
依托单位:
海外基金